Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada

Micro-Abstract This study documents the clinical course of 69 patients with high-risk chronic lymphocytic leukemia (CLL) with 11q22.3 deletion (11q-), from a provincial CLL database. Aklylator-containing chemotherapies are thought to be required to overcome the adverse prognosis associated with 11q-...

Full description

Saved in:
Bibliographic Details
Published in:Clinical lymphoma, myeloma and leukemia myeloma and leukemia, 2017-06, Vol.17 (6), p.382-389
Main Authors: Goy, Jennifer, Gillan, Tanya L, Bruyere, Helene, Huang, Steven J.T, Hrynchak, Monica, Karsan, Aly, Ramadan, Khaled, Connors, Joseph, Toze, Cynthia L, Gerrie, Alina S
Format: Article
Language:English
Subjects:
11q
Adult
Aged
Aged, 80 and over
ATM
British Columbia
Canada
Chromosomes, Human, Pair 11 - genetics
Cohort Studies
Cytogenetics
Female
Fluorescence in situ hybridization
Hematology, Oncology and Palliative Medicine
Humans
In Situ Hybridization, Fluorescence - methods
Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell - mortality
Male
Middle Aged
Prognostic factors
Sequence Deletion
Survival Analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Micro-Abstract This study documents the clinical course of 69 patients with high-risk chronic lymphocytic leukemia (CLL) with 11q22.3 deletion (11q-), from a provincial CLL database. Aklylator-containing chemotherapies are thought to be required to overcome the adverse prognosis associated with 11q-. However, most 11q- patients did not receive alkylators first-line and had a median survival of 14.7 years, comparable with the rest of the cohort.
ISSN:2152-2650
2152-2669
DOI:10.1016/j.clml.2017.04.001